| (210) | Number of the EPO application | 18729051 |
| (220) | Filing date of the EPO application | 2018.05.18 |
| (80) | EPO patent specification publication (B) | EPB nr. 17/2021, 2021.04.28 |
| (110) | EPO patent number | 3630724 |
| (21) | Number of the application | e 2020 0319 |
| (71) | Name(s) of applicant(s), code of the country | Janssen Pharmaceuticals, Inc., US;
Katholieke Universiteit Leuven, BE; |
| (72) | Name(s) of inventor(s), code of the country | BONFANTI Jean-François, FR;
KESTELEYN Bart Rudolf Romanie, BE;
BARDIOT Dorothée Alice Marie-Eve, BE;
MARCHAND Arnaud Didier M, BE;
COESEMANS Erwin, BE;
DE BOECK Benoît Christian Albert Ghislain, BE;
RABOISSON Pierre Jean-Marie Bernard, BE; |
| (73) | Name(s) of owner(s), code of the country | JANSSEN Pharmaceuticals Inc., US;
Katholieke Universiteit Leuven, BE; |
| (54) | Title of the invention | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 209/30 (2006.01.01); C07D 209/32 (2006.01.01); C07D 209/42 (2006.01.01); C07D 471/04 (2006.01.01); C07D 513/04 (2006.01.01); A61K 31/437 (2006.01.01); A61K 31/404 (2006.01.01); A61K 31/407 (2006.01.01); A61P 31/14 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.05.31 |
| (30) | Priority | 17172247, 2017.05.22, EP |
| (86) | International application | PCT/EP2018/063029, 2018.05.18 |
| (87) | International publication | WO 2018/215316, 2018.11.29 |